Skip to Content
Merck
All Photos(1)

Key Documents

L-029

Supelco

Lacosamide solution

1.0 mg/mL in acetonitrile, ampule of 1 mL, certified reference material, Cerilliant®

Sign Into View Organizational & Contract Pricing


About This Item

Empirical Formula (Hill Notation):
C13H18N2O3
CAS Number:
Molecular Weight:
250.29
MDL number:
UNSPSC Code:
41116107
PubChem Substance ID:
NACRES:
NA.24

grade

certified reference material

Quality Level

form

liquid

feature

Snap-N-Spike®/Snap-N-Shoot®

packaging

ampule of 1 mL

manufacturer/tradename

Cerilliant®

concentration

1.0 mg/mL in acetonitrile

technique(s)

gas chromatography (GC): suitable
liquid chromatography (LC): suitable

application(s)

clinical testing

format

single component solution

storage temp.

−20°C

SMILES string

CC(N[C@H](COC)C(NCC1=CC=CC=C1)=O)=O

InChI

1S/C13H18N2O3/c1-10(16)15-12(9-18-2)13(17)14-8-11-6-4-3-5-7-11/h3-7,12H,8-9H2,1-2H3,(H,14,17)(H,15,16)/t12-/m1/s1

InChI key

VPPJLAIAVCUEMN-GFCCVEGCSA-N

General description

A Certified Spiking Solution® suitable for use in LC/MS or GC/MS applications in clinical toxicology, forensic analysis, urine drug testing, prescription monitoring or pharmaceutical research. Lacosamide is a new antiepileptic drug developed for the adjunctive treatment of partial-onset seizures and diabetic neuropathic pain. The drug is marketed under the trade name Vimpat®.

Application


  • Lacosamide solution as a mass spectrometry standard: A recent development in analytical techniques features a UPLC-MS/MS method for determining lacosamide and its metabolites, essential for drug-drug interaction studies. This research underlines lacosamide′s role as a critical pharmaceutical research tool in the study of anti-epileptic drugs and their interactions (Chen et al., 2023).

  • Lacosamide as an anticonvulsant in pharmacological research: Investigations on the effects of chronic lacosamide on ovarian tissue in rats highlight the broader physiological impacts of long-term anti-seizure medication use. Such studies are critical for assessing the reproductive safety of anticonvulsants, informing guidelines for their use in women of childbearing age (Kart et al., 2022).

Legal Information

CERILLIANT is a registered trademark of Merck KGaA, Darmstadt, Germany
CERTIFIED SPIKING SOLUTION is a registered trademark of Cerilliant Corporation
Snap-N-Shoot is a registered trademark of Cerilliant Corporation
Snap-N-Spike is a registered trademark of Merck KGaA, Darmstadt, Germany
Vimpat is a registered trademark of Harris FRC Corporation

Pictograms

FlameExclamation mark

Signal Word

Danger

Hazard Classifications

Acute Tox. 4 Dermal - Acute Tox. 4 Inhalation - Acute Tox. 4 Oral - Eye Irrit. 2 - Flam. Liq. 2

Storage Class Code

3 - Flammable liquids

WGK

WGK 2

Flash Point(F)

35.6 °F - closed cup

Flash Point(C)

2 °C - closed cup


Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Molecule of the month. Lacosamide.
Drug news & perspectives, 17(10), 689-689 (2005-02-08)
G McCleane et al.
Neuroscience letters, 352(2), 117-120 (2003-11-20)
The aim of the study is to establish if the putative anticonvulsant SPM 927 has an analgesic effect in human neuropathic pain and to assess its tolerability. This is an open label study of 25 adult human subjects with resistant
Collin A Hovinga
IDrugs : the investigational drugs journal, 6(5), 479-485 (2003-06-06)
Schwarz Pharma, under license from Harris FRC, is developing SPM-927, synthesized by researchers at the University of Houston, for the potential treatment of epilepsy and neuropathic pain.

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service